Interstitial Lung Disease

Systemic sclerosis (SSc) is a disabling autoimmune disorder that can cause diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs. Affecting approximately 2 million people worldwide, SSc is challenging to diagnose due to its nonspecific symptomatology and rare nature.

The FDA has approved the first treatment — nintedanib oral capsules — to treat patients with chronic fibrosing interstitial lung diseases with a progressive phenotype, according to a press release from the agency.

The FDA has granted breakthrough therapy designation to pirfenidone for the treatment of adults with unclassifiable interstitial lung disease, according to a press release from Genentech.

A study recently published in The BMJ suggests that the number of total deaths worldwide due to chronic respiratory diseases has increased during the past 3 decades, although age-standardized mortality rates have generally declined.

Healio Pulmonology has you covered. As 2019 comes to a close, the Editors have compiled a list of updates in interstitial lung disease and idiopathic pulmonary fibrosis that Healio reported on this year.

Healio Pulmonology has you covered on some of the year’s top news from medical meetings. We bring you highlights from the American Thoracic Society International Conference and the CHEST Annual Meeting.

SAN ANTONIO — Trastuzumab deruxtecan conferred durable benefit to women with heavily pretreated HER2-posiive metastatic breast cancer, according to results of the phase 2 DESTINY-Breast01 study presented at San Antonio Breast Cancer Symposium.

The presence of interstitial lung disease at systemic sclerosis diagnosis appears to affect disease outcomes, with data indicating that even mild lung fibrosis is associated with reduced survival, according to a Norwegian study published in the American Journal of Respiratory and Critical Care Medicine.

Healio Pulmonology has compiled a list of articles highlighting the latest research and news on diagnosis and treatment for interstitial lung disease.

New data demonstrating good agreement between transbronchial lung cryobiopsy and surgical lung biopsy support the use of the technology as an alternative to surgical biopsy for patients requiring lung tissue for a diagnosis of interstitial lung disease.